Myonexus Therapeutics, a new tenant at Innovate New Albany, has just received financing from Rev1 Ventures, CincyTech, The Haim Foundation and GFB ONLUS for its next phase of clinical trials for the company’s gene therapy to treat limb-girdle muscular dystrophy (LGMD), a group of progressive, debilitating musculoskeletal diseases. Headed by New Albany resident, Mike Triplett, the company’s work led to Children’s Hospital being named a finalist for the Science “Breakthrough of the Year” award. LEARN MORE.